New chemo combo may offer hope for rare, aggressive gut cancer

NCT ID NCT04325425

Recruiting now Disease control Sponsor: Centre Hospitalier Universitaire Dijon Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a chemotherapy regimen called mFOLFIRINOX works better than the standard platinum-etoposide combination for people with a rare, fast-growing type of neuroendocrine cancer that has spread. About 218 adults with this cancer will be randomly assigned to one of the two treatments. The goal is to see which regimen delays cancer growth longer and to find genetic markers that predict which treatment is best for each person.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE; CARCINOMA

Contacts and locations

Show contact details

Locations

CH de Troyes
RECRUITING

Troyes, 10003, France

Contact Email: •••••@•••••
Centre Hospitalier de Saint Malo
RECRUITING

St-Malo, 35403, France

Contact Email: •••••@•••••
Chu Dijon Bourgogne
RECRUITING

Dijon, 21000, France

Contact Email: •••••@•••••
Chu de Caen
RECRUITING

Caen, 14033, France

Contact Email: •••••@•••••
Chu de Limoges - Dupuytren
RECRUITING

Limoges, 87042, France

Contact Email: •••••@•••••
Institut de Cancérologie de Bourgogne
RECRUITING

Dijon, 21000, France

Contact Email: •••••@•••••